Skip to main content
SpringerLink
Log in

Bioavailability of indomethacin from a modified release system containing indomethacin as the lysine salt

  • Short Communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The bioavailability of a new controlled release formulation of indomethacin lysine salt in tablets was tested in 6 healthy humans against a conventional indomethacin lysinate formulation in capsules. Both contained 100 mg of the drug, i.e. 70 mg indomethacin. Peak plasma levels were lower and more lasting and the AUC was higher with the new controlled release formulation. The latter on average produced active plasma levels for 12 h, and so it can be recommended for twice daily administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Baber N, Halliday LDC, Van Den Heuvel WJA, Walker RW, Sibeon R, Keenan JP, Littler T, Orme M (1979) Indomethacin in rheumatoid arthritis: Clinical effects, pharmacokinetics and platelet studies in responders and nonresponders. Ann Rheum Dis 38: 128–137

    Google Scholar 

  2. Helleberg L (1981) Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet 6: 245–258

    Google Scholar 

  3. Huskisson EC (1979) Routine drug treatment of rheumatoid arthritis and other rheumatic diseases. Clin Rheum Dis 5: 697–706

    Google Scholar 

  4. Flower RJ, Moncada S, Vane JR (1985) Analgesic — antipyretics and anti-inflammatory agents: drugs employed in the treatment of gout. In: Goodman Gilman A, Goodman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics, 7 edn. McMillan New York, pp 695–697

    Google Scholar 

  5. Rhymer AR, Gengos DC (1979) Indomethacin. Clin Rheum Dis 5: 541–552

    Google Scholar 

  6. Boardman PL, Hart FD (1967) Side-effects of indomethacin. Ann Rheum Dis 26: 127–132

    Google Scholar 

  7. Rothermich NO (1966) An extended study of indomethacin. J Am Med Assoc 195: 531–536

    Google Scholar 

  8. Alvàn G, Orme M, Bertilsson L, Ekstrand R, Palmer L (1975) Pharmacokinetics of indomethacin. Clin Pharmacol Ther 18: 364–373

    Google Scholar 

  9. Meier J, Nuesch E, Schmidt R (1974) Pharmacokinetic criteria for the evaluation of retard formulations. Eur J Clin Pharmacol 7: 429–432

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Drug Metabolism and Pharmacokinetics Laboratory, Real s.r.l., Villaguardia, Italy

    A. Marzo & A. Reiner

  2. Research and Development Management, Sigma Tau S.p.A., Pomezia, Italy

    E. Arrigoni Martelli

  3. Department of Pharmaceutical Chemistry, State University, Pavia, Italy

    U. Conte, P. Colombo & A. La Manna

Authors
  1. A. Marzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Reiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Arrigoni Martelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Conte
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. La Manna
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marzo, A., Reiner, A., Arrigoni Martelli, E. et al. Bioavailability of indomethacin from a modified release system containing indomethacin as the lysine salt. Eur J Clin Pharmacol 32, 85–87 (1987). https://doi.org/10.1007/BF00609963

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00609963

Key words

Search

Navigation